Equity MRK
Friday, February 26, 2021   
Asian Paints  2277.45    (-4.05%)
 
Axis Bank  724.70    (-5.98%)
 
Bajaj Auto  3800.70    (-3.55%)
 
Bajaj Finance  5238.30    (-5.28%)
 
Bajaj Finserv  9652.70    (-5.95%)
 
Bharti Airtel  557.10    (-3.81%)
 
Dr Reddy's Lab...  4424.60    (-1.22%)
 
H D F C  2539.05    (-5.40%)
 
HCL Technologi...  909.45    (-2.05%)
 
HDFC Bank  1534.35    (-4.45%)
 
Hind. Unilever  2132.05    (-1.46%)
 
ICICI Bank  597.60    (-4.83%)
 
IndusInd Bank  1063.30    (-4.19%)
 
Infosys  1252.35    (-1.76%)
 
ITC  204.05    (-2.44%)
 
Kotak Mah. Ban...  1782.35    (-5.96%)
 
Larsen & Toubr...  1442.25    (-4.27%)
 
M & M  804.85    (-6.35%)
 
Maruti Suzuki  6872.65    (-0.79%)
 
Nestle India  16097.70    (-0.10%)
 
NTPC  107.20    (-0.69%)
 
O N G C  111.15    (-6.60%)
 
Power Grid Cor...  214.80    (-5.69%)
 
Reliance Indus...  2083.85    (-2.84%)
 
St Bk of India  390.20    (-4.19%)
 
Sun Pharma.Ind...  595.30    (-2.36%)
 
TCS  2896.05    (-3.24%)
 
Tech Mahindra  918.60    (-4.09%)
 
Titan Company  1407.00    (-2.02%)
 
UltraTech Cem.  6114.60    (-4.47%)
 
Market Menu
plusminDaily Market Tracker
plusminNews
Corporate Information
Corporate Actions
Other Markets
Close
You are here : Equity | News | Hot Pursuit
Sun Pharma to launch range of Brivaracetam drug for epilepsy treatment
(15:21, 23 Feb 2021)
Brivaracetam is approved by the Drugs Controller General of India (DCGI), as an adjunctive therapy in treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.

Sun Pharma's brand, Brevipil (Brivaracetam) tablet 25 mg/50 mg/75 mg/100 mg was launched in the market on Day-1 post patent expiry of innovator product (21 February 2021). Brevipil oral solution (10 mg/ml) and injectable (10 mg/ml) will be available in the market over the next few weeks.

Brivaracetam belongs to the class of anti-epileptic drugs (AEDs) which have a unique or different mechanism of action compared to the existing treatment options. It has fast onset of action and promising efficacy.

Sun Pharmaceutical Industries reported a 87.4% jump in consolidated net profit to Rs 1,918.11 crore on 9.2% rise in net sales to Rs 8,781.84 crore in Q3 FY21 over Q3 FY20.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Shares of Sun Pharma were up 1.48% to Rs 604.55. It traded in the range of Rs 590 and Rs 608.20 so far during the day.

Powered by Capital Market - Live News